title: Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
abstract: BACKGROUND
  Reactive estrogen species cause genotoxicity and interfere with docetaxel-mediated tubulin polymerization resulting in shortened survival in men with castrate-resistant prostate cancer (CRPC).
  
  
  OBJECTIVE
  We hypothesized that polymorphisms in estrogen synthesis and estrogen targets (i.e., CYP19 and ERα) would be linked to interindividual variation in CRPC risk, docetaxel response, and overall survival in men with CRPC.
  
  
  METHODS
  Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
  
  
  RESULTS
  Patients carrying two copies of ERα polymorphisms had shorter progression-free survival on docetaxel than other patients (median survival difference ≥ 3.1 months; P ≤ 0.036). When the analysis was limited to nonobese patients, the relationship between the ERα XbaI A>G polymorphism and PFS improved (median survival difference = 3.5 months; P = 0.0078). The CYP19 R264C variant was related to the duration of survival after docetaxel in patients who were >70 years old (median survival difference =10.6 months; P=0.041). Both ERα polymorphisms were also associated with increases in CRPC risk [P ≤ 0.032; double variants vs. wild-type odds ratio ≥ 2.6], and the association with the ERα PvuII T>C also improved in those men who were <70 years old (P = 0.0073; odds ratio = 3.0).
  
  
  CONCLUSIONS
  This study demonstrates that estrogen-related genetic variation affects docetaxel clinical response and that this relationship is dependent on age and body-type in men with CRPC. Moreover, this study suggests ERα polymorphisms confer risk of developing prostate cancer, especially in men under 70 years of age.
authors.affiliation: Clinical Pharmacology Program, Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.
authors.forename: Tristan M
authors.initials: TM
authors.lastname: Sissung
authors.forename: Romano
authors.initials: R
authors.lastname: Danesi
authors.forename: C Tyler
authors.initials: CT
authors.lastname: Kirkland
authors.forename: Caitlin E
authors.initials: CE
authors.lastname: Baum
authors.forename: Sandra B
authors.initials: SB
authors.lastname: Ockers
authors.forename: Erica V
authors.initials: EV
authors.lastname: Stein
authors.forename: David
authors.initials: D
authors.lastname: Venzon
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001141:Aromatase / Q000235:genetics*; D018572:Disease-Free Survival; D000077143:Docetaxel; D047628:Estrogen Receptor alpha / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011110:Polymorphism, Genetic / Q000235:genetics; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D047628:Estrogen Receptor alpha; D043823:Taxoids; D000077143:Docetaxel; D001141:Aromatase